B3GALT5 (beta-1,3-galactosyltransferase 5)

2003-06-01  

Identity

HGNC
LOCATION
21q22.2
LOCUSID
ALIAS
B3GalT-V,B3GalTx,B3T5,GLCT5,beta-1

Other Information

Locus ID:

NCBI: 10317
MIM: 604066
HGNC: 920
Ensembl: ENSG00000183778

Variants:

dbSNP: 10317
ClinVar: 10317
TCGA: ENSG00000183778
COSMIC: B3GALT5

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000183778ENST00000343118Q9Y2C3
ENSG00000183778ENST00000380618Q9Y2C3
ENSG00000183778ENST00000380620Q9Y2C3
ENSG00000183778ENST00000398714A0A0A0MS93
ENSG00000183778ENST00000615480Q9Y2C3

Expression (GTEx)

0
5
10
15

Pathways

PathwaySourceExternal ID
Glycosphingolipid biosynthesis - lacto and neolacto seriesKEGGko00601
Glycosphingolipid biosynthesis - lacto and neolacto seriesKEGGhsa00601
Glycosphingolipid biosynthesis - globo and isoglobo seriesKEGGhsa00603
Metabolic pathwaysKEGGhsa01100
Glycosphingolipid biosynthesis, lacto-series, LacCer => Lc4CerKEGGhsa_M00070
Glycosphingolipid biosynthesis, lacto-series, LacCer => Lc4CerKEGGM00070

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
364953452022B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis.1
364953452022B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis.1
334135662021High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.9
334135662021High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.9
319368072020SSEA3 and Sialyl Lewis a Glycan Expression Is Controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 Signaling in Human ES Cells.2
322073292020Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer.9
330875592020B3GALT5 knockout alters gycosphingolipid profile and facilitates transition to human naïve pluripotency.11
319368072020SSEA3 and Sialyl Lewis a Glycan Expression Is Controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 Signaling in Human ES Cells.2
322073292020Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer.9
330875592020B3GALT5 knockout alters gycosphingolipid profile and facilitates transition to human naïve pluripotency.11
308087452019Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer.32
308087452019Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer.32
275356142017Unexpected distribution of CA19.9 and other type 1 chain Lewis antigens in normal and cancer tissues of colon and pancreas: Importance of the detection method and role of glycosyltransferase regulation.16
288834152017High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma.23
275356142017Unexpected distribution of CA19.9 and other type 1 chain Lewis antigens in normal and cancer tissues of colon and pancreas: Importance of the detection method and role of glycosyltransferase regulation.16

Citation

Dessen P

B3GALT5 (beta-1,3-galactosyltransferase 5)

Atlas Genet Cytogenet Oncol Haematol. 2003-06-01

Online version: http://atlasgeneticsoncology.org/gene/737/b3galt5-(beta-1-3-galactosyltransferase-5)